Improving therapeutic potential in breast cancer via histone deacetylase inhibitor loaded nanofibrils

Epigenetic modifications play a significant role in cancer progression, making them potential targets for therapy. Histone deacetylase inhibitors have shown promise in inhibiting cancer cell growth, including in breast cancer (BC). In this research, we examined the potential of using suberoyl anilid...

Full description

Saved in:
Bibliographic Details
Published in:Drug development research 2024-04, Vol.85 (2), p.e22172-n/a
Main Authors: Senthilkumar, Praveetha, Gogoi, Bhaskar, Dhan, Swati Smita, Subramani, Ramesh, Pushparaj, Charumathi, Mahesh, Ayyavu
Format: Article
Language:English
Subjects:
Apoptosis
Breast cancer
Cell cycle
Cell growth
Drug delivery
Drug delivery systems
Drug resistance
Epigenetics
Histone deacetylase
histone deacetylase inhibitors
Histones
Hydroxamic acid
Membrane potential
nanofibrils
Reactive oxygen species
SAHA
β‐lactoglobulin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Epigenetic modifications play a significant role in cancer progression, making them potential targets for therapy. Histone deacetylase inhibitors have shown promise in inhibiting cancer cell growth, including in breast cancer (BC). In this research, we examined the potential of using suberoyl anilide hydroxamic acid (SAHA)‐loaded β‐lg nanofibrils as a drug delivery system for triple‐negative BC cell lines. We assessed their impact on cell cycle progression, apoptosis, levels of reactive oxygen species, and mitochondrial membrane potential in cancer cells. The combination of SAHA and β‐lg nanofibrils demonstrated enhanced efficacy in inhibiting cell growth, inducing cell cycle arrest, and promoting apoptosis (43.78%) compared to SAHA alone (40.09%). Moreover, it effectively targeted cancer cells without promoting drug resistance while using a low concentration of the nanofibrils. These findings underscore the promising potential of nanofibril‐based drug delivery systems for BC treatment.
ISSN:0272-4391
1098-2299
DOI:10.1002/ddr.22172